Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance.
Overview
Mood-stabilizing medicines prevent or manage manic, depressive and recurrent episodes in bipolar disorder, but their efficacy differs by episode polarity. Lithium remains a major maintenance option, while certain antipsychotics and anticonvulsants have phase-specific roles. Treatment planning includes relapse prevention, psychotherapy and safety monitoring [1,2].
Drug classes and clinical roles
- Lithium: monovalent ion with incompletely defined mechanisms including inositol signaling and GSK-3 modulation; effective for acute mania and prevention of recurrence and associated with reduced suicide risk in several studies.
- Valproate/divalproex: enhances GABAergic effects and affects voltage-gated sodium channels; treats acute mania and selected maintenance indications, with substantial reproductive risks.
- Lamotrigine: inhibits voltage-dependent sodium channels and glutamate release; more useful for prevention of bipolar depression than for acute mania.
- Carbamazepine: voltage-gated sodium-channel blocker used in selected manic or maintenance scenarios with substantial interactions.
- Atypical antipsychotics: quetiapine, olanzapine, aripiprazole and others have approved/established roles for particular manic, depressive or maintenance phases, not identical across agents [1,2].
Treatment sequencing
NICE recommends lithium as a first-line long-term pharmacological treatment for bipolar disorder when appropriate and feasible. Acute mania commonly requires an antipsychotic, with lithium or valproate options according to response and safety. Bipolar depression treatment differs from unipolar depression; antidepressant monotherapy can trigger mania or mood instability and should not be routinely assumed safe [2].
Lithium monitoring and toxicity
Lithium is renally eliminated and has a narrow therapeutic range. Check serum concentrations at the appropriate post-dose interval according to formulation and laboratory protocol, along with kidney function, electrolytes, thyroid function, calcium and clinical symptoms. Dehydration, kidney injury and concurrent thiazide diuretics, ACE inhibitors, ARBs or NSAIDs may raise lithium levels. Tremor, vomiting, ataxia, confusion and seizures can signify toxicity and require urgent evaluation; dose and target levels must be individualized [1,2].
Valproate and lamotrigine precautions
Valproate is strongly teratogenic and associated with adverse neurodevelopmental effects after fetal exposure; regulatory restrictions also address reproductive risk in males in some jurisdictions. Check current national rules and use alternatives where appropriate. Lamotrigine requires gradual titration due to serious rash including Stevens–Johnson syndrome; valproate inhibits lamotrigine metabolism, requiring lower lamotrigine dosing. Estrogen-containing contraceptives can lower lamotrigine concentrations. Carbamazepine may cause hyponatremia and cytopenia and induces multiple metabolic enzymes [1,2].
Long-term safety
Assess metabolic effects of antipsychotics, mood symptoms, suicide risk, sleep, pregnancy planning and adherence. If discontinuing lithium, taper over weeks to months and monitor for relapse rather than stopping abruptly. Topiramate and oxcarbazepine should not be presented as established equivalent first-line mood stabilizers solely because they are anticonvulsants [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline CG185, updated guidance. Available from: https://www.nice.org.uk/guidance/cg185/chapter/recommendations
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.